Etoposide Metabolites Enhance DNA Topoisomerase II Cleavage near Leukemia-Associated MLL Translocation Breakpoints
- 12 January 2001
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 40 (5) , 1159-1170
- https://doi.org/10.1021/bi002361x
Abstract
Chromosomal breakage resulting from stabilization of DNA topoisomerase II covalent complexes by epipodophyllotoxins may play a role in the genesis of leukemia-associated MLL gene translocations. We investigated whether etoposide catechol and quinone metabolites can damage the MLL breakpoint cluster region in a DNA topoisomerase II-dependent manner like the parent drug and the nature of the damage. Cleavage of two DNA substrates containing the normal homologues of five MLL intron 6 translocation breakpoints was examined in vitro upon incubation with human DNA topoisomerase IIα, ATP, and either etoposide, etoposide catechol, or etoposide quinone. Many of the same cleavage sites were induced by etoposide and by its metabolites, but several unique sites were induced by the metabolites. There was a preference for G(−1) among the unique sites, which differs from the parent drug. Cleavage at most sites was greater and more heat-stable in the presence of the metabolites compared to etoposide. The MLL translocation breakpoints contained within the substrates were near strong and/or stable cleavage sites. The metabolites induced more cleavage than etoposide at the same sites within a 40 bp double-stranded oligonucleotide containing two of the translocation breakpoints, confirming the results at a subset of the sites. Cleavage assays using the same oligonucleotide substrate in which guanines at several positions were replaced with N7-deaza guanines indicated that the N7 position of guanine is important in metabolite-induced cleavage, possibly suggesting N7-guanine alkylation by etoposide quinone. Not only etoposide, but also its metabolites, enhance DNA topoisomerase II cleavage near MLL translocation breakpoints in in vitro assays. It is possible that etoposide metabolites may be relevant to translocations.Keywords
This publication has 9 references indexed in Scilit:
- Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemiaLeukemia, 1998
- Inhibition of the Topoisomerase II-DNA Cleavable Complex by theortho-Quinone Derivative of the Antitumor Drug Etoposide (VP-16)Biochemical and Biophysical Research Communications, 1997
- Considerable plasma levels of a cytotoxic etoposide metabolite in patients undergoing high-dose chemotherapyEuropean Journal Of Cancer, 1997
- A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase ii cleavage at dna sites distinct from those of amsacrineEuropean Journal Of Cancer, 1997
- Abasic Sites Stimulate Double-stranded DNA Cleavage Mediated by Topoisomerase IIJournal of Biological Chemistry, 1995
- Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistanceInternational Journal of Cancer, 1994
- REPAIR OF OXIDATIVE DAMAGE TO DNA: Enzymology and BiologyAnnual Review of Biochemistry, 1994
- Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugsJournal of Molecular Biology, 1991
- Structure-activity relations, cytotoxicity and topoisomerase II dependent cleavage induced by pendulum ring analogues of etoposideEuropean Journal of Cancer and Clinical Oncology, 1990